Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naltrexone delayed release - Aardvark Therapeutics

Drug Profile

Naltrexone delayed release - Aardvark Therapeutics

Alternative Names: ARD-301; DBR-LDN; SP 104

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aardvark Therapeutics
  • Developer Aardvark Therapeutics; Sorrento Therapeutics
  • Class Analgesics; Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Fibromyalgia; Pain
  • Discontinued Post acute COVID 19 syndrome

Most Recent Events

  • 20 Mar 2024 Sorrento Therapeutics plans a phase-II trial for fibromyalgia and Pain in 2024 (PO)
  • 04 Feb 2023 Discontinued - Phase-I for Post-acute-COVID-19-syndrome (In volunteers) in New Zealand (PO) (Aardvark Therapeutics pipeline, February 2023) (Sorrento Therapeutics pipeline, February 2023)
  • 11 May 2022 Adverse events data from a phase I trial in healthy volunteers released by Scilex
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top